Stockscreener 앱 받기
25.31
1.57%
0.39
전일 마감가:
$24.92
열려 있는:
$24.69
하루 거래량:
2.30M
Relative Volume:
1.13
시가총액:
$3.03B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-6.4566
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
+25.86%
1개월 성능:
+34.27%
6개월 성능:
+69.75%
1년 성능:
+204.57%
1일 변동 폭
$24.63
$25.56
1주일 범위
$19.60
$27.08
52주 변동 폭
$8.29
$27.08
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
25.31 | 3.05B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Is Arcutis Biotherapeutics Inc. stock dividend yield sustainableIPO Watch & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Arcutis Biotherapeutics Inc. stock undervalued vs historical averagesWeekly Volume Report & Target Return Focused Picks - newser.com
Leading vs lagging indicators on Arcutis Biotherapeutics Inc. performancePortfolio Profit Report & Reliable Price Breakout Alerts - newser.com
Will Arcutis Biotherapeutics Inc. stock deliver consistent dividendsJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to global recession fearsTrend Reversal & Weekly Setup with High ROI Potential - newser.com
HC Wainwright Has Positive Forecast for ARQT FY2025 Earnings - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Multi asset correlation models including Arcutis Biotherapeutics Inc.Quarterly Investment Review & Daily Oversold Bounce Ideas - newser.com
Advanced analytics toolkit walkthrough for Arcutis Biotherapeutics Inc.2025 Risk Factors & Reliable Breakout Forecasts - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Institutional & Verified Swing Trading Watchlist - newser.com
What’s the recovery path for long term holders of Arcutis Biotherapeutics Inc.July 2025 PreEarnings & Growth Focused Entry Point Reports - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 40,000 Shares - MarketBeat
Why Arcutis Biotherapeutics (ARQT) Is Up 23.9% After Expanding ZORYVE to Pediatric Atopic Dermatitis - Yahoo Finance
HC Wainwright Has Positive Outlook for ARQT Q4 Earnings - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
What the charts say about Arcutis Biotherapeutics Inc. todayChart Signals & Reliable Price Action Trade Plans - newser.com
How high can Arcutis Biotherapeutics Inc. stock go2025 Institutional Moves & Breakout Confirmation Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock poised for growthJuly 2025 Short Interest & AI Enhanced Trade Execution Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock safe for conservative investors2025 Breakouts & Breakdowns & Technical Confirmation Alerts - newser.com
Is Arcutis Biotherapeutics Inc. a candidate for recovery playJuly 2025 Intraday Action & AI Powered Buy and Sell Recommendations - newser.com
Volatility clustering patterns for Arcutis Biotherapeutics Inc.Trade Exit Report & Advanced Swing Trade Entry Plans - newser.com
Arcutis Biotherapeutics CEO Watanabe sells $1m in shares By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics CEO Watanabe sells $1m in shares - Investing.com
Goldman Sachs Maintains Arcutis Biotherapeutics (ARQT) Neutral Recommendation - Nasdaq
Roflumilast Cream 0.05% Now Commercially Available for Pediatric Atopic Dermatitis - Dermatology Times
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock - Yahoo Finance
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments - The Manila Times
Tori Spelling Joins Arcutis Biotherapeutics in Launching Free to Be Me Campaign to Raise Awareness About Eczema and Seborrheic Dermatitis - Quiver Quantitative
Arcutis (NASDAQ: ARQT) joins Tori Spelling in 'Free to Be Me' for 36M patients - Stock Titan
Arcutis Biotherapeutics (ARQT) Launches ZORYVE Cream for Young C - GuruFocus
Arcutis Biotherapeutics launches new topical cream for children's eczema - Traders Union
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 - MarketScreener
Arcutis (NASDAQ: ARQT) launches ZORYVE 0.05% cream for children 2–5 with atopic dermatitis - Stock Titan
Will earnings trigger a reversal in Arcutis Biotherapeutics Inc.Market Weekly Review & AI Driven Price Predictions - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Arcutis Biotherapeutics (ARQT) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Arcutis Biotherapeutics, Inc. $ARQT Stake Lowered by Jennison Associates LLC - MarketBeat
Why hedge funds are buying Arcutis Biotherapeutics Inc. stockJuly 2025 Market Mood & High Return Trade Guides - newser.com
Will a bounce in Arcutis Biotherapeutics Inc. offer an exitJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to inflationary pressures2025 Trade Ideas & Accurate Buy Signal Notifications - newser.com
Published on: 2025-10-30 01:04:15 - newser.com
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):